Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Global | Publication | April 7, 2020
As part of the continued efforts of the Mexican government to address and mitigate the impact of the COVID-19 outbreak, and further to resolutions relevant to the subject matter that have been issued just recently (particularly the resolution issued on March 31, 2020), on April 6, the Mexican Ministry of Health issued a new resolution seeking to elaborate and provide further clarification on the scope of “essential activities” that are allowed and encouraged to continue during the ongoing pandemic.
This new resolution is effective immediately and, in summary, provides that:
While this new resolution does not include any express penalties for companies that may fail to follow its provisions, as outlined in our prior update (available here), breach of its provisions may in fact lead to administrative and/or criminal penalties based on the existing regulation.
This is the third in Norton Rose Fulbright’s Mexico series on COVID-19 regulation and developments (other articles in this series are available here). This article is not intended to provide (nor shall it be construed as) legal advice. Feel free to reach out to Hernán González, Dante Trevedan or your Norton Rose Fulbright contact for additional updates and specific advice on how the COVID-19 outbreak may impact your deal and/or the performance of contractual or regulatory obligations under Mexican law.
Publication
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023